Hundreds of clinical trials targeting different aspects of AD, HD, and other neurodegenerative disease neuropathology—amyloid toxicity, tau toxicity, huntingtin production, oxidative stress, and neuroinflammation—have largely failed to demonstrate efficacy, with some limited success in delaying symptomatic progression [16,17,18]. This evidence concerns the gene MAPT and Alzheimer disease.